Shares of MoonLake Immunotherapeutics (MLTX) jumped in Monday trading after the company announced top-line results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa, or HS. The “strong competitor… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3735590/-Strong-competitor-data-sends-Acelyrin-to-the-moon)